Gonadorelin Dosage Guide

Evidence-based protocols for the master HPG axis regulator — pulsatile dosing for PCT, fertility support, testosterone restoration, diagnostic use, and safety.

Compiled by PeptideWiki Editorial Team·Last reviewed February 24, 2026

What Is Gonadorelin?

Gonadorelin (GnRH, gonadotropin-releasing hormone) is a synthetic decapeptide identical to endogenous GnRH produced by the hypothalamus. Its amino acid sequence is pyro-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2. Gonadorelin is the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis — the hormonal cascade that controls LH, FSH, and downstream sex hormone production in both men and women.

When administered in a pulsatile pattern (intermittent injections spaced hours apart), Gonadorelin stimulates the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH then signals the testes to produce testosterone (in men) or supports ovarian function (in women). This makes pulsatile Gonadorelin a powerful tool for HPG axis restoration, post-cycle therapy (PCT), and fertility support.

The critical distinction with Gonadorelin is pulsatile versus continuous administration. Pulsatile dosing stimulates the HPG axis. Continuous dosing paradoxically suppresses it by downregulating GnRH receptors on pituitary gonadotrophs — this is the exact mechanism used by GnRH agonist drugs like leuprolide (Lupron) for prostate cancer treatment and chemical castration. Understanding this distinction is essential before using Gonadorelin.

Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.

Dosing information in this guide is derived from clinical studies, published research, and community protocols.

Key Characteristics:

Identical to endogenous GnRH — synthetic decapeptide with the same amino acid sequence as the body’s own gonadotropin-releasing hormone (pyro-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2)
Master HPG axis regulator — stimulates pituitary release of LH and FSH, which drive testosterone production (men) and ovarian function (women)
Ultra-short half-life: 2–4 minutes — rapidly degraded by endopeptidases; this short half-life is why pulsatile dosing works — each injection creates a discrete pulse mimicking natural GnRH secretion
Pulsatile = stimulation, continuous = suppression — the CRITICAL pharmacological principle — intermittent pulses activate the HPG axis; continuous exposure downregulates GnRH receptors and suppresses LH/FSH
FDA-approved diagnostic agent — approved as Factrel for evaluating pituitary gonadotroph function; also used off-label for PCT and fertility
Strong evidence base — decades of clinical use, well-characterized pharmacology, published dose-response data in humans

For a complete overview of its mechanism and research, see our full Gonadorelin profile. New to peptides? Start with the Beginner's Guide to Peptides.

How Gonadorelin Dosage Is Determined

Gonadorelin dosing is among the best supported of all peptides used in research and clinical settings. It has been used in endocrinology for decades, and its dose-response characteristics are well-documented in published clinical studies. Dosing protocols for PCT and off-label use are derived from this clinical foundation, supplemented by community experience.

Clinical Pharmacology

The FDA-approved diagnostic protocol uses a single 100 mcg intravenous dose to evaluate pituitary function. LH and FSH are measured at baseline and at 15, 30, 45, 60, and 120 minutes post-injection. A normal response is a 3–5 fold increase in LH within 15–45 minutes. This establishes that 100 mcg is sufficient to produce a robust gonadotropin response in humans.

Pulsatile Fertility Studies

Leyendecker, Crowley, and colleagues demonstrated that pulsatile GnRH administration at 5–20 mcg IV every 60–90 minutes via pump could restore ovulation in women with hypothalamic amenorrhea and spermatogenesis in men with hypogonadotropic hypogonadism. These studies established the principle that GnRH pulse frequency and amplitude are more important than total daily dose. The pituitary responds to the pattern of stimulation, not simply the amount of peptide.

Subcutaneous PCT Protocols

Community and clinical protocols for subcutaneous Gonadorelin use higher doses per injection (50–100 mcg) to compensate for lower bioavailability compared to IV administration. Injections are spaced 2–3 times daily with at least 4–6 hours between doses to maintain the pulsatile pattern. This practical approach approximates the clinical pump protocols in a self-administrable format.

Continuous vs. Pulsatile Studies

Belchetz et al. published the landmark study demonstrating that continuous GnRH infusion in primates initially stimulates but then profoundly suppresses gonadotropin release within 1–2 weeks. This finding — confirmed in humans — is the pharmacological basis for GnRH agonist drugs (leuprolide, goserelin) used in prostate cancer and endometriosis. It is also the reason why dosing frequency is the most critical variable in Gonadorelin protocols.

Strength of evidence: Strong. Gonadorelin has decades of clinical use, FDA approval for diagnostic purposes, and extensive published research on pulsatile administration for fertility and hypogonadism. The pharmacology of pulsatile vs. continuous GnRH stimulation is one of the best-characterized phenomena in reproductive endocrinology. PCT-specific protocols are based on this clinical foundation combined with community experience.

Standard Gonadorelin Dosage Ranges

Gonadorelin is administered by subcutaneous or intramuscular injection. The route, dose, and frequency depend on the clinical context. For self-administered PCT and HPG axis support, subcutaneous injection is standard. Clinical diagnostic and fertility protocols may use IV administration.

Dosage by Context

Context	Dose per Injection	Route	Frequency	Notes
PCT / HPG Axis Support	50–100 mcg	SubQ	2–3x daily	Space injections 4–6+ hours apart; pulsatile pattern essential
Conservative / Starter	50 mcg	SubQ	2x daily	Low-dose entry point; assess LH/FSH response with blood work
Diagnostic (Clinical)	100 mcg	IV	Single dose	FDA-approved Factrel protocol; LH/FSH measured at intervals post-injection
Fertility (Clinical Pump)	5–20 mcg	IV or SubQ	Every 60–90 min	Clinical setting only; pump-driven pulsatile delivery; not practical for self-administration

Injection Timing for PCT

2x daily protocol: Morning (upon waking) + evening (before bed) — approximately 12 hours apart
3x daily protocol: Morning + mid-afternoon + before bed — approximately 6–8 hours apart
Minimum spacing: At least 4 hours between injections to allow GnRH receptor resensitization on pituitary gonadotrophs
Fasting not required: Unlike GHRPs, Gonadorelin's mechanism is not affected by food intake — inject at any time

Every-Other-Day Protocol (EOD)

Some protocols use an every-other-day (EOD) schedule with 100 mcg SubQ per injection day (1–2 injections on dosing days, rest days off). This is a more conservative approach that reduces the total number of injections while still providing pulsatile stimulation. It may be preferred for longer protocols (6–8 weeks) or when combined with a SERM.

Pulsatile dosing is non-negotiable. Every Gonadorelin injection must be spaced apart to maintain discrete LH/FSH pulses. Injecting too frequently (every 1–2 hours subcutaneously) or using very high doses without adequate spacing risks mimicking continuous GnRH exposure, which will suppress rather than stimulate the HPG axis. When in doubt, space injections further apart, not closer.

Verified sources for Gonadorelin

These vendors are vetted by PeptideWiki for purity testing and COA transparency.

SwissChemsThird-party tested research peptides10% off

SwissChems10% off

Limitless BiotechPremium nootropics & research peptides15% off

Limitless Biotech15% off

CH PeptidesResearch-grade peptides with COA transparency10% off

CH Peptides10% off

View all vendor deals·Affiliate links. Commission at no extra cost.

Pulsatile vs. Continuous: The Critical Distinction

Understanding the difference between pulsatile and continuous GnRH administration is the single most important concept for Gonadorelin use. This is not a subtle distinction — it determines whether the peptide stimulates or suppresses your reproductive hormones.

Parameter	Pulsatile Administration	Continuous Administration
Dosing Pattern	Discrete injections spaced 4–12 hours apart (SubQ) or every 60–90 min (clinical IV pump)	Constant infusion or very frequent injections without adequate spacing
Effect on GnRH Receptors	Receptors resensitize between pulses; each pulse produces a fresh LH/FSH response	Receptors downregulate and desensitize; LH/FSH release ceases
LH/FSH Response	Stimulation — increased LH and FSH release	Suppression — LH and FSH fall to castrate levels
Downstream Effect (Men)	Increased testosterone production	Testosterone crashes to near-zero
Downstream Effect (Women)	Restored ovulation and menstrual cycling	Ovarian suppression, amenorrhea
Clinical Analogy	Pulsatile GnRH pump for fertility	Leuprolide (Lupron) for prostate cancer, chemical castration
Desired for PCT?	Yes — this is the goal	No — this produces the opposite effect

Why Does This Happen?

GnRH receptors on pituitary gonadotrophs are designed to respond to pulsatile signals. The hypothalamus naturally releases GnRH in brief pulses every 60–120 minutes. Between pulses, the receptors resensitize and are primed for the next signal. When GnRH exposure is continuous, the receptors cannot reset. They undergo internalization and downregulation — the cell literally removes them from the surface. Without functional GnRH receptors, the pituitary stops responding, and LH/FSH production halts.

The Flare Effect

When continuous GnRH exposure begins, there is a brief initial surge of LH and FSH lasting 1–3 days — known as the “flare effect.” This occurs because the receptors are still functional and respond to the sustained signal. After this initial flare, receptor downregulation takes hold and gonadotropin release collapses. In clinical oncology, the flare effect must be managed (often with anti-androgens) because it can transiently increase testosterone and worsen prostate cancer symptoms before suppression takes effect.

Bottom line: If your goal is HPG axis stimulation (PCT, testosterone restoration, fertility), you MUST use pulsatile administration with adequate spacing between injections. If you accidentally mimic continuous exposure, you will suppress the very hormones you are trying to restore.

Calculate Your Gonadorelin Dose

Gonadorelin is supplied as a lyophilized (freeze-dried) powder, typically in 2 mg or 5 mg vials. You reconstitute it with bacteriostatic water, then draw your dose using an insulin syringe. The concentration depends on how much water you add to the vial.

Worked Example:

Vial size: 2 mg (2,000 mcg) of Gonadorelin
Bacteriostatic water added: 2 mL
Concentration: 2,000 mcg ÷ 2 mL = 1,000 mcg per mL
Target dose: 100 mcg
Volume to draw: 100 ÷ 1,000 = 0.1 mL = 10 units on an insulin syringe

Quick Reference — 2 mg Vial

Bac Water Added	Concentration	50 mcg Dose	100 mcg Dose
1 mL	2,000 mcg/mL	2.5 units (0.025 mL)	5 units (0.05 mL)
2 mL	1,000 mcg/mL	5 units (0.05 mL)	10 units (0.1 mL)
4 mL	500 mcg/mL	10 units (0.1 mL)	20 units (0.2 mL)

Quick Reference — 5 mg Vial

Bac Water Added	Concentration	50 mcg Dose	100 mcg Dose
2 mL	2,500 mcg/mL	2 units (0.02 mL)	4 units (0.04 mL)
2.5 mL	2,000 mcg/mL	2.5 units (0.025 mL)	5 units (0.05 mL)
5 mL	1,000 mcg/mL	5 units (0.05 mL)	10 units (0.1 mL)

Skip the Math — Use Our

Enter your vial size, water volume, and desired dose — get instant calculations with zero manual math.

Gonadorelin Dosage by Goal

Gonadorelin's primary use cases center on HPG axis modulation — restoring, supporting, or evaluating the hormonal cascade that drives LH, FSH, and sex hormone production. The optimal protocol depends on whether you are targeting post-cycle recovery, fertility support, testosterone maintenance, or diagnostic evaluation.

Post-Cycle Therapy (PCT) — HPG Axis Restoration

The most common use of Gonadorelin in the research peptide community. After a cycle of anabolic steroids or SARMs, the HPG axis is suppressed — endogenous GnRH, LH, FSH, and testosterone production are all reduced. Pulsatile Gonadorelin restimulates the pituitary to resume LH/FSH secretion, kickstarting the recovery cascade. Best results are achieved when combined with a SERM.

Dose: 50–100 mcg per injection (SubQ)
Frequency: 2–3x daily, spaced 4–8 hours apart
Duration: 4–8 weeks depending on degree of suppression
Stack: + Enclomiphene 12.5–25 mg daily (SERM for estrogen feedback blockade) for synergistic HPG axis recovery
Blood work: Baseline LH, FSH, total T, free T, estradiol before starting; recheck at 4 weeks

Testosterone Maintenance & HCG Alternative

Some TRT (testosterone replacement therapy) protocols use Gonadorelin as an alternative or adjunct to HCG for maintaining testicular function and fertility while on exogenous testosterone. While exogenous testosterone suppresses the HPG axis, pulsatile Gonadorelin can maintain some degree of pituitary LH output and testicular stimulation. This is particularly relevant for men who want to preserve fertility potential while on TRT.

Dose: 50–100 mcg per injection (SubQ)
Frequency: 2x daily or every other day
Duration: Ongoing while on TRT (cycling may be advisable)
Goal: Maintain testicular volume, spermatogenesis, and intratesticular testosterone while on exogenous T
Note: Effectiveness may be limited when exogenous testosterone strongly suppresses the HPG axis; individual response varies

Fertility Support — Hypothalamic Hypogonadism

The most well-established clinical application of pulsatile GnRH. For men or women with hypogonadotropic hypogonadism (where the hypothalamus fails to produce adequate GnRH), pulsatile Gonadorelin can restore the full HPG signaling cascade — including ovulation in women and spermatogenesis in men. Clinical protocols use IV pump delivery, but subcutaneous protocols have also been studied.

Clinical protocol: 5–20 mcg IV every 60–90 minutes via portable pump (clinical setting)
Subcutaneous alternative: 50–100 mcg SubQ, 2–3x daily
Duration: Variable; fertility protocols may run weeks to months under medical supervision
Monitoring: LH, FSH, estradiol (women) or testosterone (men), ultrasound for follicle development (women), semen analysis (men)

Fertility protocols require medical supervision. Pulsatile GnRH therapy for fertility is a well-established clinical treatment, but it requires hormone monitoring, imaging, and dose adjustments that cannot be done independently. Work with a reproductive endocrinologist for fertility applications.

Diagnostic Testing — Pituitary Function

The FDA-approved use of Gonadorelin (Factrel). A single 100 mcg IV bolus is administered and LH/FSH are measured at intervals to evaluate whether the pituitary gonadotrophs are functional. A normal response (3–5x LH increase within 15–45 minutes) confirms pituitary reserve. An absent or blunted response suggests pituitary insufficiency.

Dose: 100 mcg IV (single dose)
Blood draws: Baseline, 15 min, 30 min, 45 min, 60 min, 120 min
Context: Clinical/diagnostic only; performed by a physician
Interpretation: Normal = 3–5x LH rise; blunted = possible pituitary dysfunction; absent = pituitary failure

Choose the protocol that matches your goal. For PCT, pulsatile SubQ dosing with a SERM is the standard approach. For fertility, medical supervision with pump-driven delivery is ideal. For diagnostic use, a single IV dose is all that is needed. The common thread is understanding that the pulsatile pattern is what drives the therapeutic effect.

Cycling & Duration

Unlike GHRPs (where cycling prevents receptor desensitization), Gonadorelin cycling is driven by the clinical context. PCT protocols have defined durations. Fertility protocols run as long as needed. The key consideration is not desensitization (since pulsatile dosing avoids that) but rather the goal-specific treatment window.

Protocol Duration by Goal

Goal	Duration	Cycling	Notes
PCT (Mild Suppression)	4 weeks	Single course	For shorter or milder cycles; confirm recovery with blood work
PCT (Moderate–Heavy)	6–8 weeks	Single course	For longer or more suppressive cycles; SERM recommended as co-treatment
TRT Adjunct	Ongoing	8 weeks on / 4 weeks off (optional)	Some protocols run continuously; cycling may help maintain receptor sensitivity
Fertility	Weeks to months	Continuous until goal achieved	Under medical supervision; adjusted based on hormone monitoring
Diagnostic	Single dose	None	One-time 100 mcg IV bolus for pituitary function testing

PCT Timeline Example

A typical 6-week PCT protocol using Gonadorelin + enclomiphene after a moderate anabolic steroid cycle:

Week 0: Baseline blood work (LH, FSH, total T, free T, estradiol, SHBG)
Weeks 1–6: Gonadorelin 100 mcg SubQ 2x daily (morning + evening) + Enclomiphene 12.5–25 mg daily
Week 4: Follow-up blood work to assess progress
Week 6: End Gonadorelin; may continue enclomiphene 1–2 weeks longer if recovery incomplete
Week 8: Final blood work to confirm HPG axis recovery

Blood work is essential. Gonadorelin's effects are hormonal and not reliably assessed by subjective symptoms alone. LH, FSH, and testosterone measurements are the only way to confirm whether the pulsatile protocol is working. Always get baseline labs before starting and follow-up labs during and after the protocol.

Gonadorelin Stacking Protocols

Gonadorelin is most commonly stacked with compounds that complement its HPG axis stimulation — primarily SERMs (selective estrogen receptor modulators) that block estrogen's negative feedback on the hypothalamus and pituitary, amplifying the effect of GnRH stimulation. It can also be used in protocols that include or replace HCG.

Gonadorelin + Enclomiphene — The Gold Standard PCT Stack

The most widely recommended PCT combination. Gonadorelin provides direct pulsatile GnRH stimulation of pituitary gonadotrophs, while enclomiphene (a pure estrogen receptor antagonist) blocks estrogen's negative feedback at the hypothalamus and pituitary. This dual approach attacks HPG suppression from both sides — direct stimulation plus removal of the brake.

Compound	Dose	Frequency	Purpose
Gonadorelin	50–100 mcg SubQ	2–3x daily (pulsatile)	Direct pulsatile GnRH stimulation of pituitary LH/FSH release
Enclomiphene	12.5–25 mg oral	1x daily	Blocks estrogen negative feedback at hypothalamus/pituitary; amplifies endogenous GnRH and LH output

Why this works: During PCT, estrogen (aromatized from residual androgens or from adipose tissue) exerts negative feedback that suppresses GnRH, LH, and FSH. Enclomiphene blocks this feedback, allowing both endogenous GnRH pulses and exogenous Gonadorelin to have maximum effect on pituitary gonadotrophs. The result is faster and more complete HPG axis recovery than either compound alone.

Gonadorelin + Clomiphene (Classic PCT)

Similar mechanism to the enclomiphene stack, but using clomiphene citrate (Clomid), which contains both enclomiphene (estrogenic antagonist) and zuclomiphene (estrogenic agonist). Clomiphene is more widely available but carries more estrogen-related side effects than pure enclomiphene due to the zuclomiphene component.

Compound	Dose	Frequency	Purpose
Gonadorelin	50–100 mcg SubQ	2–3x daily (pulsatile)	Pulsatile GnRH stimulation of pituitary gonadotrophs
Clomiphene (Clomid)	25–50 mg oral	1x daily	SERM; blocks estrogen negative feedback; more side effects than enclomiphene

Gonadorelin as HCG Replacement (TRT Adjunct)

Following FDA regulatory changes that restricted compounding pharmacy access to HCG, some TRT clinics have adopted Gonadorelin as an alternative for maintaining testicular function during testosterone replacement therapy. While the mechanisms differ (HCG mimics LH directly; Gonadorelin stimulates endogenous LH via pituitary), the goal is the same: preserve testicular volume, intratesticular testosterone, and spermatogenesis while on exogenous testosterone.

Compound	Dose	Frequency	Purpose
Testosterone (TRT)	Per physician protocol	Per physician protocol	Exogenous testosterone replacement
Gonadorelin	50–100 mcg SubQ	2x daily (pulsatile)	Maintain pituitary LH output and testicular function while on TRT

Note on HCG replacement: Whether pulsatile Gonadorelin is as effective as HCG for maintaining testicular function during TRT is still debated. HCG directly stimulates Leydig cells (bypassing the pituitary), while Gonadorelin requires a functional pituitary that may be suppressed by exogenous testosterone. Individual results vary. Blood work monitoring (LH, testosterone, semen analysis) is essential to evaluate effectiveness.

HCG → Gonadorelin Sequential (Comprehensive PCT)

Some comprehensive PCT protocols begin with HCG to provide immediate testicular stimulation (bypassing the still-suppressed pituitary), then transition to Gonadorelin + SERM to restore the full HPG signaling cascade from the top down. This sequential approach addresses both immediate testosterone recovery and long-term axis restoration.

Phase	Compound	Dose	Duration
Phase 1 (HCG Bridge)	HCG	250–500 IU SubQ, every other day	2–3 weeks
Phase 2 (GnRH + SERM)	Gonadorelin + Enclomiphene	Gonadorelin 100 mcg SubQ 2x daily + Enclomiphene 12.5–25 mg daily	4–6 weeks

Do NOT combine Gonadorelin with GnRH agonists or antagonists. GnRH agonists (leuprolide, goserelin) and GnRH antagonists (degarelix, cetrorelix) directly interfere with Gonadorelin's mechanism. Agonists cause sustained receptor downregulation; antagonists block the receptor entirely. Neither should be used concurrently with pulsatile Gonadorelin for HPG stimulation.

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Safety, Side Effects & Contraindications

Safety Profile: Gonadorelin is one of the best-characterized peptides with decades of clinical use and FDA approval as a diagnostic agent. At proper pulsatile doses, it is very well tolerated. The primary safety concern is not acute side effects but rather the risk of inadvertent continuous administration, which produces the opposite of the intended effect (HPG suppression). Proper dosing frequency is the most important safety consideration.

Common Side Effects

Generally mild and transient at standard pulsatile doses:

Headache — the most commonly reported side effect; usually mild and resolves with continued use
Nausea — occasional, typically mild; more common with higher doses
Injection site reactions — redness, mild pain, or swelling at the injection site; standard for subcutaneous peptide administration
Abdominal discomfort — infrequent; reported in some clinical studies
Light-headedness or flushing — transient, usually resolves within minutes post-injection

Less common:

Local skin reactions at injection site — itching, hives (rare; may indicate sensitivity)
Multi-dose hypersensitivity — rare allergic-type reactions with repeated administration (reported in clinical literature but uncommon)

The Primary Risk: Inadvertent Continuous Administration

The most significant risk with Gonadorelin is not an acute side effect but a dosing error. If injections are spaced too closely or doses are too large and frequent, the pulsatile pattern is lost, and the effect transitions from HPG stimulation to HPG suppression. Symptoms of inadvertent continuous-pattern dosing include:

In men: Declining testosterone, low libido, erectile dysfunction, fatigue, mood changes, testicular atrophy — the opposite of what PCT aims to achieve
In women: Amenorrhea, hot flashes, vaginal dryness, bone density concerns with prolonged suppression
Initial flare: A brief 1–3 day surge of LH/testosterone before suppression takes hold (may be mistaken for the protocol “working”)

If you suspect HPG suppression from incorrect dosing: Stop Gonadorelin immediately. The pituitary GnRH receptors will resensitize over days to weeks once continuous exposure stops. Get blood work (LH, FSH, testosterone) to confirm your hormonal status. If suppression has occurred, standard PCT with a SERM may be needed to recover.

Contraindications

Pregnancy — Gonadorelin can affect gonadotropin levels and potentially disrupt pregnancy. Contraindicated in pregnant women.
Hormone-sensitive cancers — pulsatile GnRH stimulation increases LH, FSH, and downstream sex hormones. This could theoretically stimulate hormone-sensitive tumors (breast, prostate, endometrial). Avoid use in patients with hormone-sensitive malignancies.
Known hypersensitivity — allergy to Gonadorelin or any component of the formulation. Rare but documented.
Pituitary apoplexy or recent pituitary surgery — stimulating a damaged or recently operated pituitary is not advisable.
Concurrent GnRH agonist or antagonist therapy — pharmacological conflicts; do not use Gonadorelin with leuprolide, goserelin, degarelix, or cetrorelix.

When to Stop or Seek Medical Attention

Signs of allergic reaction (rash, swelling, difficulty breathing) — stop immediately and seek emergency care
Signs of HPG suppression despite pulsatile dosing (declining libido, fatigue, testicular atrophy) — stop, get blood work, reassess protocol
Blood work showing declining LH/FSH/testosterone during a stimulation protocol — indicates the pulsatile pattern is not effective; reassess dosing frequency
Severe or persistent headaches, nausea, or abdominal pain — reduce dose or discontinue

Regulatory Status: Gonadorelin is FDA-approved under the brand name Factrel as a diagnostic agent for evaluating pituitary gonadotroph function. It is a prescription peptide. Off-label use for PCT and fertility is common but not FDA-indicated. Research-grade Gonadorelin is available from peptide suppliers. Regulations vary by jurisdiction.

Common Gonadorelin Dosing Mistakes

Avoid these common errors to get the most out of your Gonadorelin protocol:

Dosing too frequently (mimicking continuous administration): This is the most dangerous mistake with Gonadorelin. Injecting every 1–2 hours or using very frequent small doses can mimic continuous GnRH exposure, which paradoxically suppresses the HPG axis instead of stimulating it. Space injections at least 4–6 hours apart for subcutaneous protocols. The goal is discrete pulses, not a constant signal.

Using Gonadorelin without understanding pulsatile vs. continuous: Pulsatile Gonadorelin stimulates the HPG axis. Continuous Gonadorelin suppresses it. This is not a subtle distinction — it is the difference between restoring testosterone production and crashing it. Before starting Gonadorelin, you must understand this fundamental pharmacological principle.

Expecting an immediate testosterone response: Gonadorelin stimulates LH and FSH release from the pituitary, which then signals the testes to produce testosterone. This cascade takes time. LH may rise within hours of a pulse, but meaningful testosterone recovery takes days to weeks. PCT protocols typically run 4–8 weeks because HPG axis restoration is a gradual process, not an overnight event.

Using Gonadorelin as a standalone PCT: While Gonadorelin can stimulate pituitary LH/FSH release, it is most effective when combined with a SERM (enclomiphene or clomiphene) that blocks estrogen’s negative feedback on the hypothalamus and pituitary. Using Gonadorelin alone may produce suboptimal results because estrogen-mediated suppression of GnRH signaling remains active.

Confusing Gonadorelin with GnRH agonists (leuprolide, goserelin): GnRH agonists like leuprolide are long-acting analogs designed for continuous receptor stimulation — they suppress the HPG axis on purpose. Gonadorelin is identical to native GnRH and has a 2–4 minute half-life, making it suitable for pulsatile stimulation. These are pharmacologically opposite approaches despite both acting on GnRH receptors.

Not spacing injections far enough apart: Each Gonadorelin pulse must be followed by a recovery period where GnRH receptors on the pituitary resensitize. If injections are too close together (under 3–4 hours for subcutaneous), the pituitary cannot reset between pulses, and the effect begins to resemble continuous stimulation. Maintain at least 4–6 hours between subcutaneous injections.

Storing reconstituted Gonadorelin improperly: Gonadorelin is a delicate decapeptide that degrades rapidly when improperly stored. Once reconstituted with bacteriostatic water, it must be refrigerated (2–8°C) and used within 2–4 weeks. Do not freeze reconstituted peptide. Do not leave it at room temperature. Degraded Gonadorelin will produce a diminished or absent LH/FSH response.

Using high doses thinking more is better: Gonadorelin’s effectiveness depends on pulsatile timing, not dose magnitude. The standard 50–100 mcg subcutaneous dose is sufficient to stimulate a robust LH pulse. Doses above 100–200 mcg per injection do not produce proportionally greater LH release and may actually contribute to receptor desensitization if the pituitary is overstimulated.

Neglecting blood work to confirm the protocol is working: Gonadorelin’s effects are hormonal and not easily felt subjectively. Without blood work (LH, FSH, total testosterone, free testosterone, estradiol), you have no way to confirm whether the pulsatile protocol is actually stimulating your HPG axis. Get baseline labs before starting and follow-up labs at 2–4 weeks.

Frequently Asked Questions

Key Takeaways

Gonadorelin is identical to endogenous GnRH — the master regulator of the HPG axis controlling LH, FSH, and downstream sex hormone production
Pulsatile = stimulation, continuous = suppression — this is the most critical concept. Intermittent pulsed injections stimulate the HPG axis; continuous exposure paradoxically suppresses it
Standard PCT dose: 50–100 mcg SubQ, 2–3x daily — space injections at least 4–6 hours apart to maintain pulsatile pattern
Ultra-short half-life (2–4 minutes) — rapid clearance ensures each injection creates a discrete pulse mimicking natural GnRH secretion
Gold standard PCT stack: Gonadorelin + enclomiphene for synergistic HPG axis restoration (direct GnRH stimulation + estrogen feedback blockade)
FDA-approved as Factrel for diagnostic testing of pituitary function; well-characterized pharmacology with decades of clinical use
PCT duration: 4–8 weeks depending on degree of HPG suppression; blood work essential to confirm recovery
Can serve as HCG alternative for maintaining testicular function during TRT, though effectiveness may vary by individual
Fasting not required — unlike GHRPs, Gonadorelin's mechanism is not affected by food intake. Consistency of pulsatile timing matters most.
Blood work is essential — LH, FSH, total testosterone, free testosterone, and estradiol at baseline and during the protocol. Subjective symptoms alone cannot confirm hormonal recovery.

This article is for educational and informational purposes only. See our Disclaimer.

References

Belchetz PE, et al. “Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone.” Science. 1978;202(4368):631-633. PubMed
Crowley WF Jr, et al. “The physiology of gonadotropin-releasing hormone (GnRH) secretion in men and women.” Recent Prog Horm Res. 1985;41:473-531. PubMed
Leyendecker G, et al. “Induction of ovulation with chronic intermittent (pulsatile) administration of LH-RH in women with hypothalamic and hyperprolactinemic amenorrhea.” Arch Gynecol. 1980;229(3):177-190. PubMed
Schally AV, et al. “Hypothalamic regulatory hormones.” Science. 1973;179(4071):341-350. PubMed
Conn PM, Crowley WF Jr. “Gonadotropin-releasing hormone and its analogues.” N Engl J Med. 1991;324(2):93-103. PubMed
Hoffman AR, Crowley WF Jr. “Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone.” N Engl J Med. 1982;307(20):1237-1241. PubMed
Nestor JJ Jr, et al. “A long-acting LHRH agonist: design, synthesis and biological evaluation.” Life Sci. 1984;34(14):1377-1385.
Santoro N, et al. “Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin-releasing hormone.” Endocr Rev. 1986;7(1):11-23. PubMed
Factrel (gonadorelin hydrochloride) prescribing information. FDA approved labeling. Wyeth-Ayerst Laboratories.

Next Steps

Continue your research with these resources.

PT-141 Dosage Guide

Learn dosing protocols for PT-141 (Bremelanotide) — another peptide that interacts with reproductive pathways through melanocortin receptor activation.

Read Guide

Dosage Calculator

Calculate your exact Gonadorelin dose based on vial size and reconstitution volume.

Open Calculator

Peptide Directory

Browse all peptides with research summaries and dosing data.

View Directory